First Parkinson’s patient dosed with USP30 inhibitor

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Mission Therapeutics has begun a 36-patient Phase 1b study of MTX325, a drug aimed at clearing out damaged mitochondria in the brain.

Every cell in your body runs on mitochondria, tiny power plants that wear out like any other machinery. Cells have a cleanup routine for the broken ones. A British biotech now wants to see whether switching that routine up could change the course of Parkinson’s disease.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 3560

Mission Therapeutics

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.
  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.

Overview

Mission Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule deubiquitylating enzyme (DUB) inhibitors to treat serious diseases characterized by mitochondrial dysfunction. The company's lead program targets USP30, a mitochondrial DUB that inhibits mitophagy—the cellular quality control process responsible for removing damaged mitochondria. By selectively inhibiting USP30, Mission's therapeutics aim to restore normal mitochondrial function and cellular health across multiple disease indications including Parkinson's disease, heart failure, Duchenne muscular dystrophy, and other neurodegenerative and mitochondrial disorders. Mission's proprietary DUB platform combines novel disease biology, bespoke screening tools, and unique chemistry to generate a pipeline of highly potent and selective candidates with substantial clinical and commercial potential.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Kyle Umipig

Kyle has nine years of editorial writing experience. They have been following the longevity sector since 2022, focusing on research, emerging tech, and the companies shaping the future of aging and age-related health.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE